title: Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: preparation, in vitro and in vivo studies.
abstract: The aim of this study was to evaluate a nanoparticulate system with mucoadhesion properties composed of a core of polymethyl methacrylate surrounded by a shell of thiolated chitosan (Ch-GSH-pMMA) for enhancing oral bioavailability of docetaxel (DTX), an anticancer drug. DTX-loaded nanoparticles were prepared by emulsion polymerization method using cerium ammonium nitrate as an initiator. Physicochemical properties of the nanoparticles such as particle size, size distribution, morphology, drug loading, and entrapment efficiency were characterized. The pharmacokinetic study was carried out in vivo using wistar rats. The half-life of DTX-loaded NPs was about 9 times longer than oral DTX used as positive control. The oral bioavailability of DTX was increased to 68.9% for DTX-loaded nanoparticles compared to 6.5% for positive control. The nanoparticles showed stronger effect on the reduction of the transepithelial electrical resistance (TEER) of Caco-2 cell monolayer by opening the tight junctions. According to apparent permeability coefficient (P(app)) results, the DTX-loaded NPs showed more specific permeation across the Caco-2 cell monolayer in comparison to the DTX. In conclusion, the nanoparticles prepared in this study showed promising results for the development of an oral drug delivery system for anticancer drugs.
authors: Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
authors: Shahrooz
authors: S
authors: Saremi
authors: Rassoul
authors: R
authors: Dinarvand
authors: Abbas
authors: A
authors: Kebriaeezadeh
authors: Seyed Nasser
authors: SN
authors: Ostad
authors: Fatemeh
authors: F
authors: Atyabi
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D018938:Caco-2 Cells; D048271:Chitosan / Q000737:chemistry*; D004058:Diffusion; D000077143:Docetaxel; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D053769:Nanocapsules / Q000008:administration & dosage* / Q000737:chemistry* / Q000648:ultrastructure; D019904:Polymethyl Methacrylate / Q000737:chemistry*; D051381:Rats; D017208:Rats, Wistar; D013438:Sulfhydryl Compounds / Q000737:chemistry; D043823:Taxoids / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics*; D014018:Tissue Distribution
chemical_list: D000970:Antineoplastic Agents; D053769:Nanocapsules; D013438:Sulfhydryl Compounds; D043823:Taxoids; D000077143:Docetaxel; D019904:Polymethyl Methacrylate; D048271:Chitosan
references: J Pharm Sci. 2009 Aug;98(8):2718-30
references: 18972321
references: Pharmacogenetics. 1998 Oct;8(5):391-401
references: 9825831
references: J Nanosci Nanotechnol. 2009 Aug;9(8):4593-603
references: 19928123
references: Cancer Res. 2011 Apr 15;71(8):3018-28
references: 21363913
references: J Clin Oncol. 2001 Feb 15;19(4):1160-6
references: 11181682
references: J Control Release. 2004 Nov 5;100(1):87-95
references: 15491813
references: Anticancer Drugs. 2010 Jan;21(1):43-52
references: 19809300
references: Pharm Res. 2003 Nov;20(11):1812-9
references: 14661926
references: Eur J Pharm Sci. 2007 Feb;30(2):143-54
references: 17157487
references: Expert Opin Pharmacother. 2005 Dec;6(15):2719-26
references: 16316310
references: J Control Release. 2009 Dec 3;140(2):79-85
references: 19712714
references: J Clin Oncol. 2005 Jan 20;23(3):422-31
references: 15659489
references: Eur J Pharm Sci. 2008 Jan;33(1):1-8
references: 17980561
references: Biomaterials. 2005 Oct;26(30):6068-76
references: 15894372
references: Nanomedicine. 2010 Oct;6(5):689-97
references: 20172052
references: Pharm Res. 2004 Jan;21(1):43-9
references: 14984256
references: Pharm Res. 1994 Sep;11(9):1358-61
references: 7816770
references: Drug Dev Ind Pharm. 2008 Nov;34(11):1227-37
references: 18720137
references: Int J Nanomedicine. 2011 Jan 12;6:119-28
references: 21289989
references: Lancet. 1994 Nov 5;344(8932):1267-72
references: 7967989
references: Invest New Drugs. 2001 May;19(2):155-62
references: 11392449
references: J Control Release. 2004 Dec 10;100(3):331-46
references: 15567500
references: Int J Pharm. 2008 Feb 12;349(1-2):226-33
references: 17825506
references: Eur J Pharm Biopharm. 2004 Jan;57(1):115-21
references: 14729087
references: Int J Pharm. 2003 Jul 24;260(2):229-37
references: 12842342
references: Cancer Chemother Pharmacol. 2005 Jan;55(1):72-8
references: 15316750
references: J Control Release. 2010 Jul 1;145(1):2-8
references: 20347897
references: Anticancer Drugs. 1996 Aug;7 Suppl 2:33-6
references: 8862709
references: Nanomedicine. 2009 Jun;5(2):208-15
references: 19186220
references: Eur J Pharm Biopharm. 2008 Sep;70(1):270-8
references: 18492606
references: J Control Release. 2009 Dec 3;140(2):86-94
references: 19709639
references: Pharm Res. 2006 Jun;23(6):1243-50
references: 16715372
references: J Pharm Sci. 1992 Sep;81(9):879-87
references: 1432633
references: Anticancer Drugs. 2000 Nov;11(10):813-20
references: 11142688
references: Eur J Pharm Sci. 2000 Oct;11(4):333-41
references: 11033077
references: Nanoscale Res Lett. 2011 Dec;6(1):4
references: 27502629
references: J Control Release. 2006 Mar 10;111(1-2):228-34
references: 16458988
references: Invest New Drugs. 2001 May;19(2):125-41
references: 11392447
references: Acta Pharm. 2009 Jun;59(2):133-44
references: 19564139